Glycomimetics Inc financial data

Symbol
GLYC on Nasdaq
Industry
Pharmaceutical Preparations
Location
9708 Medical Center Drive, Rockville, Maryland
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 755 % +4.27%
Debt-to-equity 15.3 % -2.23%
Return On Equity -88.4 % -8.92%
Return On Assets -76.6 % -9.25%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 64.5 M shares +0.32%
Common Stock, Shares, Outstanding 64.5 M shares +0.32%
Entity Public Float 109 M USD +254%
Common Stock, Value, Issued 64.5 K USD +0.32%
Weighted Average Number of Shares Outstanding, Basic 64.5 M shares +6.81%
Weighted Average Number of Shares Outstanding, Diluted 64.5 M shares +6.81%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 20.7 M USD -14.6%
General and Administrative Expense 18.8 M USD -3.95%
Operating Income (Loss) -39.4 M USD +9.69%
Net Income (Loss) Attributable to Parent -37.3 M USD +12.1%
Earnings Per Share, Basic -0.58 USD/shares +25.6%
Earnings Per Share, Diluted -0.58 USD/shares +25.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 31.3 M USD -51.9%
Assets, Current 33.3 M USD -51.1%
Property, Plant and Equipment, Net 133 K USD -53.8%
Operating Lease, Right-of-Use Asset 598 K USD +12.4%
Assets 34.2 M USD -50.4%
Accounts Payable, Current 756 K USD +57.4%
Accrued Liabilities, Current 3.91 M USD -30.3%
Liabilities, Current 5.29 M USD -21.5%
Operating Lease, Liability, Noncurrent 66.8 K USD
Liabilities 5.29 M USD -21.5%
Retained Earnings (Accumulated Deficit) -467 M USD -8.67%
Stockholders' Equity Attributable to Parent 28.9 M USD -53.5%
Liabilities and Equity 34.2 M USD -50.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.5 M USD +9.46%
Net Cash Provided by (Used in) Financing Activities 28.8 M USD +593%
Net Cash Provided by (Used in) Investing Activities -7.44 K USD -239%
Common Stock, Shares Authorized 100 M shares 0%
Common Stock, Shares, Issued 64.5 M shares +0.32%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.5 M USD -161%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 76.5 M USD -42.2%
Deferred Tax Assets, Valuation Allowance 161 M USD +7.59%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 162 M USD +7.48%
Operating Lease, Liability 631 K USD -3.21%
Depreciation 124 K USD -35.3%
Payments to Acquire Property, Plant, and Equipment 7.44 K USD +239%
Lessee, Operating Lease, Liability, to be Paid 660 K USD -0.13%
Property, Plant and Equipment, Gross 2.64 M USD +0.54%
Operating Lease, Liability, Current 631 K USD -3.21%
Lessee, Operating Lease, Liability, to be Paid, Year Two 67.4 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 67.4 K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 29.4 K USD +213%
Deferred Tax Assets, Operating Loss Carryforwards 88.7 M USD +7.2%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) 0 USD
Preferred Stock, Shares Authorized 5 M shares 0%
Operating Lease, Payments 934 K USD -15.9%
Additional Paid in Capital 496 M USD +0.81%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 211 K USD -39.8%
Share-based Payment Arrangement, Expense 3.85 M USD +5.46%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%